D.E. Shaw & Co
ACUR

D.E. Shaw & Co’s Acura Pharmaceuticals ACUR Stock Holding History

D.E. Shaw & Co’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,210
Closed -$12K – 4584
2014
Q2 		$12K Sell
2,210
-101
-4% -$612 ﹤0.01% 4131
2014
Q1 		$17K Buy
+2,311
New +$20.1K ﹤0.01% 4220
2013
Q3 		– Sell
-15,216
Closed -$143K – 4569
2013
Q2 		$143K Buy
+15,216
New +$172K ﹤0.01% 3825

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

D.E. Shaw & Co's ACUR Position: Q3 2014 in Review

D.E. Shaw & Co sold out of Acura Pharmaceuticals (ACUR) in Q3 2014, closing a stake of 2,210 shares — an estimated $12K sold.

D.E. Shaw & Co first reported a position in ACUR in Q2 2013 and held it in 3 quarters. The position peaked at $143K in Q2 2013. 28 funds tracked by Wall St. Rank hold ACUR as of Q3 2014.

  • D.E. Shaw & Co reported no remaining Acura Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • D.E. Shaw & Co sold 2,210 Acura Pharmaceuticals shares in Q3 2014, an estimated $12K.
  • D.E. Shaw & Co first reported a position in Acura Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • D.E. Shaw & Co's Acura Pharmaceuticals position peaked at $143K in Q2 2013.
  • 28 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q3 2014.

Based on D.E. Shaw & Co's 13F filing for Q3 2014, filed 14 Nov 2014.